Showing 5031-5040 of 20470 results for "".
- Multiomic Blood Signatures Forecast Trauma Outcomes: CU Anschutz Reporthttps://reachmd.com/news/multiomic-blood-signatures-trauma-outcomes/2485672/Investigators at the University of Colorado Anschutz are using longitudinal plasma multiomic pro
- AI Footprint Grows in Aesthetic Surgery: Analysishttps://reachmd.com/news/ai-footprint-grows-in-aesthetic-surgery-specialty-analysis/2485685/Artificial intelligence (AI) is increasingly embedded in plastic surgery, according to a narrative review published in Aesthetic Surgery Journal. Authors used PubMed searches of arti
- Finnish Registry Study Finds No Link Between Abortion, Miscarriage, and Breast Cancer Riskhttps://reachmd.com/news/finnish-registry-study-finds-no-link-between-abortion-miscarriage-and-breast-cancer-risk/2485659/A large nationwide study from Finland adds robust evidence to a longstanding and often politicized debate: neither induced abortion nor miscarriage appears to increase a woman’s subsequent ri
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://reachmd.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Tolebrutinib Not Shown to Reduce Confirmed Disability Progression in Adults with Primary Progressive Multiple Sclerosishttps://reachmd.com/news/tolebrutinib-does-not-reduce-confirmed-disability-progression-in-adults-with-primary-progressive-multiple-sclerosis/2485651/Treatment with the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib (Sanofi, Bridgewater, NJ) did not significantly delay disability progression in people with primary progressive multiple sclerosis (PPMS) according to results from the phase 3 PERSEUS trial (NCT04458051) presen
- Survey Shows Declines in Perceived Safety of MMR and Flu Vaccineshttps://reachmd.com/news/perceived-safety-mmr-flu-vaccines/2485653/In a survey of 1,637 adults, the majority described the MMR, influenz
- Regeneron at AAAAI 2026: First Phase‑3 Allergen‑Challenge Readouts and Dupixent sBLAhttps://reachmd.com/news/regeneron-at-aaaai-2026-first-phase3-allergenchallenge-readouts-and-dupixent-sbla/2485661/In a February 10, 2026 press release, Regeneron says AAAI 2026 immunology abstracts spanning 36 abstract
- Merz Aesthetics Marks 15 Years of XEOMIN® With New National Campaignhttps://reachmd.com/news/merz-aesthetics-marks-15-years-of-xeomin-with-new-national-campaign/2485650/Merz Aesthetics is commemorating 15 years since the US Food and Drug Administration (FDA) approved XEOMIN® (incobotulinumtoxinA) for aesthetic use, marking a milestone for the company’s flagship neurotoxin in the competitive US injectable market. Approved f
- CooperVision’s MiSight 1 day Becomes First Pediatric Myopia-Control Contact Lens Available in Japanhttps://reachmd.com/news/coopervisions-misight-1-day-becomes-first-pediatric-myopia-control-contact-lens-available-in-japan/2485642/CooperVision has begun offering its MiSight 1 day myopia-control contact lenses in Japan, marking the first time a soft contact lens with regulatory authorization for slowing nearsightedness progression in children has entered the country’s vision care market. The
- Anxiety Sensitivity Shapes Whether Bystanders Step In During Bullying, VR Study Findshttps://reachmd.com/news/anxiety-sensitivity-shapes-whether-bystanders-step-in-during-bullying-vr-study-finds/2485640/A new experimental study suggests that how individuals interpret their own anxiety may be a critical factor in determining whether they intervene when witnessing bullying. Using a virtual reality (VR) simulation